Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cara Therapeutics (NQ: CARA )

0.3724 +0.0073 (+2.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cara Therapeutics

< Previous 1 2 Next >
Cara Therapeutics Announces Exploration of Strategic Alternatives
Piper Sandler & Co. to act as financial advisor 
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Reports First Quarter 2024 Financial Results
Topline efficacy and safety results from KOURAGE 1 Part A portion of notalgia paresthetica (NP) pivotal program now expected by the end of 2Q24 
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Reports Third Quarter 2023 Financial Results
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
Approval triggers $1.5 million milestone payment to Cara 
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Inc. (NASDAQ: CARA) Leading the Way in Friday Trading Based on Percentage Gain
Via Investor Brand Network
Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Reports Second Quarter 2023 Financial Results
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics to Present at the Jefferies Healthcare Conference
From Cara Therapeutics, Inc.
Via GlobeNewswire
Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in... 
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Reports First Quarter 2023 Financial Results
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine
Publication underscores the importance of data in underrecognized neuropathic itch disorder which lacks an approved treatment 
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.